Literature DB >> 29099920

Achieving 90-90-90 Human Immunodeficiency Virus (HIV) Targets Will Not Be Enough to Achieve the HIV Incidence Reduction Target in Australia.

Nick Scott1,2, Mark Stoové1,2, Sherrie L Kelly1,2, David P Wilson1, Margaret E Hellard1,2,3.   

Abstract

Background: We estimated the human immunodeficiency virus (HIV) incidence reduction in Australia that would correspond to achieving the United Nations Program on HIV and AIDS (UNAIDS) 90-90-90 targets by 2020 and extended targets of 95-95-95 by 2030. This was done in combination with various scale-ups of HIV testing, primary prevention, and preexposure prophylaxis (PrEP) among high-risk men who have sex with men (MSM). These projections were evaluated against the target of achieving a 90% reduction in HIV incidence by 2030 compared with 2010 levels.
Methods: A mathematical model.
Results: Achieving 90-90-90 by 2020 was estimated to reduce incidence by 10% from 2010 levels. Achieving 95-95-95 by 2030 was estimated to reduce incidence by 17% from 2010 levels, with the first "95" being achievable by testing low- and high-risk MSM 2 and 4 times per year, respectively. This was improved to a 34% reduction by including a 5-year scale-up of PrEP to 30% coverage among high-risk MSM and to 45% by also increasing MSM condom use from 42% to 60%. However, even with 95-95-95, 2 and 4 tests per year for low- and high-risk MSM, 100% high-risk MSM PrEP coverage, and 100% MSM condom use, only an 80% reduction in incidence was possible by 2030. Conclusions: Many countries, particularly those with low HIV prevalence, will struggle to achieve a 90% reduction in HIV incidence by 2030, even if UNAIDS targets are met. Most will require substantially higher levels of prevention coverage and higher testing frequencies to reach this target.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29099920     DOI: 10.1093/cid/cix939

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

1.  HIV Digital Vaccine Strategy: Proposal for Applying Blockchain in Preventing the Spread of HIV.

Authors:  Jia Liu
Journal:  JMIR Res Protoc       Date:  2022-06-13

2.  Evidence of an Association of Increases in Pre-exposure Prophylaxis Coverage With Decreases in Human Immunodeficiency Virus Diagnosis Rates in the United States, 2012-2016.

Authors:  Dawn K Smith; Patrick S Sullivan; Betsy Cadwell; Lance A Waller; Azfar Siddiqi; Robertino Mera-Giler; Xiaohong Hu; Karen W Hoover; Norma S Harris; Scott McCallister
Journal:  Clin Infect Dis       Date:  2020-12-15       Impact factor: 9.079

3.  A tale of two countries: progress towards UNAIDS 90-90-90 targets in Botswana and Australia.

Authors:  Tafireyi Marukutira; Mark Stoové; Shahin Lockman; Lisa A Mills; Tendani Gaolathe; Refeletswe Lebelonyane; Joseph N Jarvis; Sherrie L Kelly; David P Wilson; Stanley Luchters; Suzanne M Crowe; Margaret Hellard
Journal:  J Int AIDS Soc       Date:  2018-03       Impact factor: 5.396

4.  Shifting the HIV Paradigm from Care to Cure: Proceedings from the Caribbean Expert Summit in Barbados, August 2017.

Authors:  R Clive Landis; E Akinola Abayomi; Brendan C Bain; Edward Greene; George Janossy; Patrice Joseph; Deanna Kerrigan; J Philip McCoy; Cesar Nunez; Maurice O'Gorman; Alexander Pastoors; Bharat S Parekh; Kim R Quimby; Thomas C Quinn; Kevin R Robertson; Réjean Thomas; Eric van Gorp; Sten H Vermund; Valerie Wilson
Journal:  AIDS Res Hum Retroviruses       Date:  2018-06-05       Impact factor: 2.205

5.  Modelling the epidemiologic impact of achieving UNAIDS fast-track 90-90-90 and 95-95-95 targets in South Africa.

Authors:  N N Abuelezam; A W McCormick; E D Surface; T Fussell; K A Freedberg; M Lipsitch; G R Seage
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

6.  Pre-exposure prophylaxis (PrEP) for MSM in low HIV incidence places: should high risk individuals be targeted?

Authors:  Ngai Sze Wong; Tsz Ho Kwan; Owen T Y Tsang; Man Po Lee; Wing Cheong Yam; Wilson Lam; Wai Shing Leung; Jacky M C Chan; Kai Man Ho; Shui Shan Lee
Journal:  Sci Rep       Date:  2018-08-03       Impact factor: 4.379

7.  Monitoring the Control of Sexually Transmissible Infections and Blood-Borne Viruses: Protocol for the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS).

Authors:  Denton Callander; Clarissa Moreira; Margaret Hellard; Rebecca Guy; Carol El-Hayek; Jason Asselin; Caroline van Gemert; Lucy Watchirs Smith; Long Nguyen; Wayne Dimech; Douglas Ir Boyle; Basil Donovan; Mark Stoové
Journal:  JMIR Res Protoc       Date:  2018-11-20

8.  Gaps in the HIV diagnosis and care cascade for migrants in Australia, 2013-2017: A cross-sectional study.

Authors:  Tafireyi Marukutira; Richard T Gray; Caitlin Douglass; Carol El-Hayek; Clarissa Moreira; Jason Asselin; Basil Donovan; Tobias Vickers; Tim Spelman; Suzanne Crowe; Rebecca Guy; Mark Stoove; Margaret Hellard
Journal:  PLoS Med       Date:  2020-03-10       Impact factor: 11.069

9.  Population Impact and Efficiency of Improvements to HIV PrEP Under Conditions of High ART Coverage Among San Francisco Men Who Have Sex With Men.

Authors:  Adrien Le Guillou; Susan Buchbinder; Hyman Scott; Albert Liu; Diane Havlir; Susan Scheer; Samuel M Jenness
Journal:  J Acquir Immune Defic Syndr       Date:  2021-12-01       Impact factor: 3.771

10.  Trends in late and advanced HIV diagnoses among migrants in Australia; implications for progress on Fast-Track targets: A retrospective observational study.

Authors:  Tafireyi Marukutira; Praveena Gunaratnam; Caitlin Douglass; Muhammad S Jamil; Skye McGregor; Rebecca Guy; Richard Thomas Gray; Tim Spelman; Danielle Horyniak; Nasra Higgins; Carolien Giele; Suzanne Mary Crowe; Mark Stoove; Margaret Hellard
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.